Uic

San Rocco Therapeutics is dedicated to developing therapies for life-threatening rare diseases, rooted in a personal journey that began in 1992 when founder Patrick Girondi's son was diagnosed with Thalassemia. The enterprise evolved from pioneering gene therapy initiatives and collaborative clinical trials, focusing primarily on Sickle Cell Disease and Thalassemia, making significant strides in bringing affordable gene therapy to patients. With a commitment to benevolence, mirroring the accomplishments of the patron saint it is named after, San Rocco has spearheaded numerous partnerships with prominent research institutions and hospitals worldwide. The company continues to pave the way for innovative treatments, driven by a deep dedication to improving the lives of those affected by these rare hematological conditions. Generated from the website

Peter B. Bensinger and Dr. Robert L. DuPont, leading authorities in employee assistance programs and substance abuse intervention and prevention founded Bensinger, DuPont & Associates in 1982. A privately owned professional services company, BDA employee welfare and also offers consultation services to individuals and families. It also offers a wide range of consultation, training and counseling services, including personal and family crisis help lines, training and supervisory support and safety trainings. In addition, BDA provides a 24-hour counseling service for gambling addiction and drug and alcohol testing programs. BDA has corporate offices in Chicago, Washington D.C., Little Rock, Ark., and San Diego, along with more than 1,200 branch offices located throughout the United States.

CDG Therapeutics Inc. is a biotechnology company based in Chicago, specializing in the development and commercialization of proprietary peptides derived from both pathogenic and nonpathogenic bacteria and green plants. These innovative peptides are designed to selectively enter cancer cells, inducing cell cycle arrest and leading to cell death. The company's focus on harnessing the unique properties of these peptides positions it at the forefront of cancer therapy research, contributing to advancements in treatment options. Through its commitment to science and technology, CDG Therapeutics aims to make significant strides in the fight against cancer. Generated from the website